<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146977</url>
  </required_header>
  <id_info>
    <org_study_id>C-020</org_study_id>
    <nct_id>NCT01146977</nct_id>
  </id_info>
  <brief_title>Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)</brief_title>
  <acronym>CBF(+)AML</acronym>
  <official_title>Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with&#xD;
      core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5.2 AUTOLOGOUS PBSCS HARVESTING&#xD;
&#xD;
      5.2.1. PBSCs will be collected during recovery phase after the second cycle of HDAC&#xD;
      consolidation chemotherapy.&#xD;
&#xD;
      5.2.2. For mobilization, recombinant human granulocyte- colony-stimulating factor (G-CSF,&#xD;
      Filgrastim) will be given subcutaneously at a dose of 10 mcg/kg from day 9 of the 2nd HDAC&#xD;
      cycle until the completion of harvesting.&#xD;
&#xD;
      5.2.3. PBSCs harvesting will be performed via perm-cath or Quinton catheter, which will be&#xD;
      inserted with fluoroscopy-guided before starting and will be removed after finishing harvest.&#xD;
&#xD;
      5.2.4. Harvest will be initiated from the day when the peripheral absolute neutrophil count&#xD;
      reach up to 0.2 x 109/mm3. Peripheral blood mononuclear cells will be collected by&#xD;
      leukapheresis method with 'CS-3000' (Baxter, Deerfield, IL) or other compatible machine. Cell&#xD;
      collection will be performed for at least 2 days and the duration of collection can be&#xD;
      extended until a target CD34+ cell dose of 5 x 106/kg (in terms of body weight of recipient)&#xD;
      is collected.&#xD;
&#xD;
      5.2.5. If adequate numbers of CD34+ cells are not collected, the 3rd HDAC chemotherapy will&#xD;
      be done and mobilization/harvest procedure will be repeated.&#xD;
&#xD;
      5.2.6. Stem cells harvested from patient will be frozen in liquid nitrogen tank for future&#xD;
      autologous HCT cell infusion.&#xD;
&#xD;
      5.3.PRETRANSPLANT WORKUP FOR AUTOLOGOUS HCT 5.3.1. Pre-workup for checking the current&#xD;
      disease status and feasibility for autologous HCT will be performed before the conditioning&#xD;
      and infusion of autologous HCT.&#xD;
&#xD;
      5.3.2. It is recommended that baseline workup for hematologic / non-hematologic status will&#xD;
      be performed at least 1 month prior to the initiation of conditioning. Bone marrow aspirate/&#xD;
      biopsy with cytogenetics and diagnostic lumbar puncture can be performed immediately before&#xD;
      the initiation of conditioning.&#xD;
&#xD;
      5.3.3. Pretransplant workup tests are listed in Appendix IV.&#xD;
&#xD;
      5.4. CONDITIONING REGIMEN FOR AUTOLOGOUS HCT 5.4.1. On admission, 5.4.1.1.Menstruating women&#xD;
      will be given norethindrone (Norlutate) 10mg po daily until platelet count is consistently&#xD;
      over 100,000 /mcL.&#xD;
&#xD;
      5.4.1.2.Actual body weight (ABW) for busulfan will be calculated using following guidelines;&#xD;
      5.4.1.2.1.If ABW is less or equal to ideal body weight (IBW), use ABW. 5.4.1.2.2.If ABW is&#xD;
      greater than IBW but ABW is within 120% of IBW, use IBW. 5.4.1.2.3.If ABW is 120% or greater&#xD;
      than IBW, use IBW+25% (ABW-IBW). 5.4.1.2.4.IBW(ideal body weight) will be calculated in&#xD;
      5.4.1.2.4.1.Male: 50 kg + 2.3kg (height[inch]-60) 5.4.1.2.4.2.Female: 45.5kg + 2.3kg&#xD;
      (height[inch]-60) 5.4.1.2.4.3.1inch=2.54cm 5.4.2. On day -8, preparation drugs will be&#xD;
      administered to patient as below; 5.4.2.1.Hydration with 0.9% normal saline will be started&#xD;
      at 6PM and infused continuously at a rate of 100mL/hr through day -4.&#xD;
&#xD;
      5.4.2.2.Allopurinol 300mg/day will be taken p.o. once a day from day-8 to -2. 5.4.2.3.Heparin&#xD;
      100 U/kg/day in normal saline 500 mL will be infused continuously at a rate of 20mL/hr&#xD;
      through day 20 (6pm). Heparin should be discontinued if there is clinically significant&#xD;
      bleeding or aPTT level exceeds 1.2 time of the upper normal limit.&#xD;
&#xD;
      5.4.2.4.Dilantin 15mg/kg (ABW) in normal saline 300cc will be infused continuously at a rate&#xD;
      of 200mL/hr at 8PM, and then, 200mg will be taken p.o. twice a day through day -4. Dilantin&#xD;
      level should be monitored in the morning of day-7 and -6 to maintain the level within 10 to&#xD;
      20 mg/L.&#xD;
&#xD;
      5.4.3. From day-7, conditioning drug will be administered to patient as below;&#xD;
      5.4.3.1.Busulfan 3.2mg/kg/day in normal saline of 10 times the volume of busulfan will be&#xD;
      infused continuously over 3 hours with an interval of 24 hours on days -7 to -5 (for 3 days).&#xD;
&#xD;
      5.4.3.2.Etoposide 200mg/m2/day in normal saline 1000mL will be infused continuously over 5&#xD;
      hours twice a day with an interval of 12 hours on day-3 to -2 (for 2 days).&#xD;
&#xD;
      5.4.3.3.Antiemetics such as serotonin antagonist or lorazepam are allowed.&#xD;
&#xD;
      5.5. AUTOLOGOUS PBSCS INFUSION 5.5.1. Autologous PBSCs will be infused on day0.&#xD;
      5.5.1.1.Premedication including pheniramine maleate (avil) 45.5mg i.v., acetaminophen 600mg&#xD;
      p.o., hydrocortisone 250mg i.v. and furosemide 20mg i.v. will be given 30 minutes before cell&#xD;
      infusion.&#xD;
&#xD;
      5.5.1.2.PBSCs will be infused via saline infusion set without in-line filters. 5.5.1.3.Vital&#xD;
      sign should be checked 4 times with 15 minutes of interval, 4 times with 30 minutes, and then&#xD;
      4 times with 1 hour. Electrocardiogram monitoring will be performed from the start until the&#xD;
      completion of PBSCs infusion.&#xD;
&#xD;
      5.5.1.4.Following medications should not be administered simultaneously with PBSCs;&#xD;
      5.5.1.4.1.Lipid-containing total parenteral nutrition fluid 5.5.1.4.2.Conventional or&#xD;
      liposomal amphotericin 5.6. SUPPORTIVE CARE 5.6.1. Recombinant human G-CSF (rhG-CSF) 450㎍ in&#xD;
      100 mL of D5W will be infused intravenously over 30 minutes from day 5 till ANC&gt;3,000/㎕.&#xD;
&#xD;
      5.6.2. Ciprofloxacin 500mg will be given p.o. twice a day (for selective bowel&#xD;
      decontamination) from day 1 till ANC&gt;3,000/㎕. With the first fever spike, ciprofloxacin can&#xD;
      be replaced with broad spectrum antibiotics.&#xD;
&#xD;
      5.6.3. Micafungin 50mg will be infused intravenously once a day from day1 till ANC&gt;3,000/㎕.&#xD;
&#xD;
      5.6.4. Acyclovir 250mg/m2 will be infused twice a day from day1 till ANC&gt;3,000/㎕.&#xD;
&#xD;
      5.6.5. In case of oral mucositis, sodium bicarbonate/saline mouthwash will be applied four&#xD;
      times a day until resolved.&#xD;
&#xD;
      5.6.6. Clotrimazole or Canesten® powder can be applied to groin, axilla, and perianal area&#xD;
      twice a day from day-8 until engraftment.&#xD;
&#xD;
      5.6.7. All cellular blood products must be transfused after leukocyte filtration and&#xD;
      irradiation.&#xD;
&#xD;
      5.6.8. For woman of childbearing potential, adequate consultation for ovarian protection can&#xD;
      be sought. For man who intend to have child(ren) in future, sperm banking can be recommended&#xD;
      and performed.&#xD;
&#xD;
      5.7. EVALUATION DURING TREATMENT 5.7.1. CBC with differential count, ALT/AST, bilirubin with&#xD;
      BUN/Cr, and electrolyte will be checked once daily.&#xD;
&#xD;
      5.7.2. Chemical battery with BUN/phosphorus, LDH and level of magnesium will be checked three&#xD;
      times a week.&#xD;
&#xD;
      5.7.3. Coagulation battery with fibrinogen/d-dimer will be checked at day 0, 7, 14, 21 and&#xD;
      once a week thereafter until discharge.&#xD;
&#xD;
      5.7.4. Protein C, antithrombin III, t-PA antigen, and PAI-1 antigen will be checked at day 0,&#xD;
      7, 14, and 21.&#xD;
&#xD;
      5.7.5. Urinalysis will be checked once a week. 5.7.6. Chest X-ray will be checked once a week&#xD;
      routinely and more frequently according to patient's condition.&#xD;
&#xD;
      5.7.7. Blood galactomannan (aspergillosis antigen, GM) assay can be recommended to be checked&#xD;
      once a week until ANC&gt;3,000/ according to the physician's decision.&#xD;
&#xD;
      5.8. POST-HCT FOLLOW-UP INCLUDING MRD MONITORING 5.8.1. Patients will be followed with&#xD;
      physical examination and appropriate blood test including CBC at least every 3 months for 3&#xD;
      years, every 6 months for the next 2 years, and then annually thereafter.&#xD;
&#xD;
      5.8.2. Toxicities related to treatment will be assessed and reported according to NCI CTCAE&#xD;
      v3.0.&#xD;
&#xD;
      5.8.3. Minimal residual disease (MRD) monitoring with RQ-PCR for AML1/ETO or CBFβ/MYH11 will&#xD;
      be performed before autologous HCT (bone marrow and peripheral blood, 1 month after&#xD;
      autologous HCT (bone marrow and peripheral blood), and thereafter, every 3 months (peripheral&#xD;
      blood only) until 3 years after autologous HCT.&#xD;
&#xD;
      5.8.4. If RQ-PCR is not available, RT-PCR and/or FISH can be used for MRD monitoring&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CIR, DFS</measure>
    <time_frame>6 years</time_frame>
    <description>Relapse incidence (cumulative incidence of relapse, CIR)&#xD;
Disease-free survival (DFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRM, EFS, OS</measure>
    <time_frame>6 years</time_frame>
    <description>Engraftment rate / time to engraftment&#xD;
Transplantation-related mortality (TRM)&#xD;
Event-free survival (EFS)&#xD;
Overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Autologous HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.&#xD;
5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDAC chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HDAC chemotherapy</intervention_name>
    <description>If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.</description>
    <arm_group_label>HDAC chemotherapy</arm_group_label>
    <other_name>Cytarabine 3g/m2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous HCT</intervention_name>
    <description>After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.&#xD;
If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue.</description>
    <arm_group_label>Autologous HCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CBF positive AML in CR1. CBF AML includes t(8;21)(q22;q22)&#xD;
             [AML1(RUNX1)/ETO(CBFα2T1)], inv(16)(q13q22) (CBFβ/MYH11),t(16;16)(p13;q22)&#xD;
             (CBFβ/MYH11) Using RT-PCR, FISH, or standard karyotype analysis technique.&#xD;
&#xD;
          -  Patients who plan to receive the second cycle of HDAC consolidation chemotherapy.&#xD;
&#xD;
          -  15 years old or older and 65 years or younger&#xD;
&#xD;
          -  Adequate performance status (Karnofsky score of 70 or more).&#xD;
&#xD;
          -  Adequate hepatic and renal function (AST, ALT, and bilirubin &lt; 3.0 x upper normal&#xD;
             limit, and creatinine &lt; 2.0 mg/dL).&#xD;
&#xD;
          -  Adequate cardiac function (left ventricular ejection fraction over 40% on heart scan&#xD;
             or echocardiography)&#xD;
&#xD;
          -  Signed and dated informed consent must be obtained from patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of significant active infection&#xD;
&#xD;
          -  Presence of uncontrolled bleeding&#xD;
&#xD;
          -  Any coexisting major illness or organ failure&#xD;
&#xD;
          -  Patients with psychiatric disorder or mental deficiency severe as to make compliance&#xD;
             with the treatment unlike, and making informed consent impossible&#xD;
&#xD;
          -  Nursing women, pregnant women, women of childbearing potential who do not want&#xD;
             adequate contraception&#xD;
&#xD;
          -  Patients with a diagnosis of prior malignancy unless disease-free for at least 5 years&#xD;
             following therapy with curative intent (except curatively treated nonmelanoma skin&#xD;
             cancer, in situ carcinoma, or cervical intraepithelial neoplasia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae-Young Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dae-Young Kim, professor</last_name>
    <phone>82-2-3010-5930</phone>
    <email>dani@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Asanbyeongwon-gil, songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yae Eun Jang, nurse</last_name>
      <phone>82-2-3010-6378</phone>
      <email>redpin75@paran.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.google.co.kr</url>
    <description>Autologous hematopoietic cell transplantation for core-binding factor positive acute myeloid leukemia in the first complete remission</description>
  </link>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>COSAH</name_title>
    <organization>Cooperative Study Group A for Hematology</organization>
  </responsible_party>
  <keyword>CBF(+)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

